CureVac N.V. (a Dutch company) [ • ] Common Shares UNDERWRITING AGREEMENTUnderwriting Agreement • January 25th, 2021 • CureVac N.V. • Pharmaceutical preparations • New York
REDACTED Certain identified information, indicated by [*****], has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. SECOND AMENDMENT TO COLLABORATION AND LICENSE...Collaboration and License Agreement • January 25th, 2021 • CureVac N.V. • Pharmaceutical preparations
This SECOND AMENDMENT TO COLLABORATION AND LICENSE AGREEMENT (“ Second Amendment”) is made the 15thnd day of December 2020 (“Second Amendment Effective Date”), by and between:
REDACTED Certain identified information, indicated by [*****], has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. AMENDMENT 4 to DEFINITIVE AGREEMENT 1 Investment...Definitive Agreement • January 25th, 2021 • CureVac N.V. • Pharmaceutical preparations
THIS AMENDMENT amends, and is made part of, the above-referenced Agreement and is effective as of the Amendment Effective Date. Capitalized terms not defined in this Amendment will have the meaning provided in the Agreement. Except as modified by this Amendment, all other terms and conditions of the Agreement remain in full force and effect. By signing below, each Party acknowledges that it has carefully read and fully understood this Amendment, and each agrees to be bound by its terms. Facsimile and electronic signatures will be binding for all purposes.
Addendum to the Shareholders' AgreementCureVac N.V. • January 25th, 2021 • Pharmaceutical preparations
A In clause 8 ("Investment Commitment DH") of the shareholders' agreement concluded between the parties (with the exception of DH-LT Investments GmbH) with regard to the parties' shareholdings in CureVac N.V. (NL-Amsterdam) dated 16 June 2020 ("Shareholders' Agreement"), DH has undertaken to invest an amount of EUR 100 million into CureVac N.V. on the occasion of the IPO in order to acquire shares at economic terms and in particular at a share price corresponding to the issue price of a share in the IPO ("concurrent private placement") ("Investment Amount").
REDACTED Certain identified information, indicated by [*****], has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed.CureVac N.V. • January 25th, 2021 • Pharmaceutical preparations
THIS AMENDMENT NUMBER 1 is made by and between Partner and CEPI, either of which may be referred to individually as a "Party" and together as the "Parties."
Amendment Three to Development and Option AgreementDevelopment and Option Agreement • January 25th, 2021 • CureVac N.V. • Pharmaceutical preparations
This Amendment Three to the Development and Option Agreement (this "Amendment"), dated as of December 24, 2020 (the "Amendment Three Effective Date"), is made by and between CureVac AG, a German stock corporation with offices at Friedrich-Miescher-Strasse 15, 72076 Tübingen, Germany ("CureVac"), and Acuitas Therapeutics Inc., a British Columbia corporation with offices at 6190 Agronomy Road, Suite 405, Vancouver, British Columbia, V6T 1Z3, Canada ("Acuitas") and amends the Development and Option Agreement dated April 29, 2016 (as amended by Side Agreement and Amendment Number One dated December 1, 2016 and Amendment Two to the Development and Option Agreement dated July 10, 2020) between CureVac and Acuitas (as amended, the “Development and Option Agreement”). Each of CureVac and Acuitas may be referred to herein as a "Party" or together as the "Parties."
REDACTED Certain identified information, indicated by [*****], has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. 1st Amendment to the DEVELOPMENT AND LICENSE...Development and License Agreement • January 25th, 2021 • CureVac N.V. • Pharmaceutical preparations
